查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968522

傷口皮膚替代材料市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、最終用戶、地區和競爭格局分類，2021-2031年

Wound Skin Substitutes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球傷口皮膚替代品市場預計將從 2025 年的 17.6 億美元成長到 2031 年的 27.5 億美元，複合年成長率為 7.72%。

這些替代材料包括生物來源、合成材料和生物合成材料，旨在修復或取代受損的皮膚組織，在治療糖尿病足潰瘍、靜脈性腿部潰瘍和嚴重燒燙傷等慢性疾病中發揮至關重要的作用。這些產品透過模擬細胞外基質，促進細胞再生並加速傷口縫合。推動市場擴張的一個主要因素是慢性疾病（尤其是糖尿病）在全球範圍內的日益流行，這導致需要有效潰瘍管理的患者數量顯著增加。例如，根據國際糖尿病聯盟 (IDF) 的報告，到 2024 年，全球將有約 5.89 億成年人患有糖尿病，這為這些治療藥物的廣泛應用提供了巨大的基礎。

市場概覽
預測期 2027-2031
市場規模：2025年 17.6億美元
市場規模：2031年 27.5億美元
複合年成長率：2026-2031年 7.72%
成長最快的細分市場 慢性傷口
最大的市場 北美洲

儘管市場具有巨大的成長潛力，但由於這些先進療法的高昂成本，市場面臨許多障礙。嚴格的報銷政策和不同醫療體系之間保險覆蓋範圍的差異，往往構成經濟障礙。這些經濟壁壘會限制患者獲得必要的醫療干預，並阻礙市場整體成長。

市場促進因素

慢性文明病（尤其是糖尿病和肥胖症）發生率的上升，是推動傷口皮膚替代物應用的主要動力。這些生理狀況往往會損害人體自身的自然癒合過程，導致複雜的糖尿病足潰瘍，需要以細胞治療方法進行治療。世界衛生組織（WHO）預測，到2024年，全球將有超過10億人患有肥胖症，而肥胖症與循環功能障礙和傷口癒合延遲之間存在科學關聯。如此龐大的患者族群需要利用生物工程皮膚結構來治療慢性皮膚缺陷。此外，區域統計數據也凸顯了代謝性疾病負擔的日益惡化。根據英國糖尿病協會2024年5月的報告，英國糖尿病患者人數達到創紀錄的560萬，這意味著易患嚴重皮膚併發症的人數正在增加。

同時，組織工程技術的快速發展以及胎盤和羊膜同種異體移植的商業性正在推動市場成長。製造商不斷推出具有調節發炎和最大限度減少疤痕的多功能替代產品，促使醫療專業人員放棄傳統的傷口敷料。再生醫學解決方案的擴展在主要市場參與企業的財務表現中得到了清晰的體現。例如，MiMedx集團於2024年2月公佈，其2023會計年度的年度淨銷售額為3.215億美元。這項業績主要歸功於該公司先進創傷護理產品組合的廣泛應用。這些財務數據表明，在臨床實踐中，治療難癒合傷口的方法正朝著使用生物工程替代療法的方向發生實際轉變。

市場挑戰

先進創傷護理產品成本不斷上漲，加上複雜的報銷體系，對皮膚替代物市場的成長構成重大阻礙。醫療保健系統面臨著控制成本的巨大壓力，導致這些昂貴的生物來源和生物合成材料的核准標準日益嚴格。這使得支付方經常採用嚴格的文件標準和不一致的支付政策，為醫療服務提供者帶來財務不確定性。這種經濟環境，加上持續存在的高拒付和少付風險，使得醫院和專科診所不願儲備或開立此類治療藥物。

這種限制性環境直接影響市場進入和產品推廣。據傷口護理利益相關者相關人員稱，提案的2023年地方醫保覆蓋範圍決定可能會削弱約200種細胞和組織衍生產品的創傷護理保險報銷合格。此類政策變化限制了醫生可選擇的臨床方案，並阻礙了患者獲得可能挽救肢體的治療。當監管障礙削弱了經濟可行性時，創新皮膚替代品的推廣速度就會放緩，從而阻礙全球市場的整體獲利能力和成長。

市場趨勢

在對經濟高效的治療方案和更便捷的患者就醫途徑的需求推動下，創傷護理服務向門診機構和門診手術中心的轉移正在顯著改變市場格局。醫療服務提供者正在加速傷口管理的去中心化，減少患者長時間住院，轉而採用配備攜帶式自動化再生醫學技術的專科診所。這一趨勢簡化了低危險環境下的傷口治療，在維持臨床療效的同時，減輕了醫療系統的經濟負擔。根據Avita Medical截至2025年1月的會計年度財報，其季度商業收入約為1,840萬美元，較上一季成長30%。這一成長主要得益於該公司即時再生醫學設備在不斷擴展的治療環境中的加速部署。

同時，無細胞真皮基質（ADM）和合成支架的應用日益廣泛。與傳統的細胞療法相比，這些材料具有明顯的優勢。與難以保存且有免疫抗原性風險的細胞同種異體移植不同，無細胞異種移植和合成基質能夠提供穩定、即用型的支架，促進與活體組織的整合和新生血管形成。這些材料在複雜重組手術中展現的供應可靠性和結構完整性，進一步支撐了這個趨勢。財務數據也印證了這項需求。 Integra Life Sciences 2025會計年度財報顯示，其傷口重組板塊實現了8.2%的內部成長，這主要得益於DuraSorb和MicroMatrix等生物工程和合成基質產品銷售額的低兩位數成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球傷口皮膚替代市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用範圍（慢性傷口、急性傷口、其他）
    • 按最終使用者（醫院、門診手術中心、專科診所等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美傷口皮膚替代市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲傷口皮膚替代材料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區傷口皮膚替代材料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲傷口皮膚替代材料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲傷口皮膚替代材料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球傷口皮膚替代材料市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Coloplast A/S
  • Smith & Nephew plc
  • MTF Biologics
  • MIMEDX, Inc.
  • AVITA Medical, Inc.
  • MISONIX, Inc.
  • Mallinckrodt Pharmaceuticals
  • Tissue Regenix Ltd
  • Vericel Corporation
  • Integra LifeSciences Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24087

The Global Wound Skin Substitutes Market is projected to expand from USD 1.76 Billion in 2025 to USD 2.75 Billion by 2031, registering a compound annual growth rate of 7.72%. These substitutes encompass biological, synthetic, and biosynthetic materials designed to repair or replace damaged dermal tissue, playing a vital role in treating chronic conditions like diabetic foot ulcers, venous leg ulcers, and severe burns. By mimicking the extracellular matrix, these products promote cellular regeneration and expedite wound closure. A primary factor fueling this market expansion is the escalating global prevalence of chronic diseases, specifically diabetes, which vastly increases the number of patients needing effective ulcer management. For example, the International Diabetes Federation reported that approximately 589 million adults were living with diabetes globally in 2024, providing a significant basis for the increased utilization of these therapeutic agents.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.76 Billion
Market Size 2031USD 2.75 Billion
CAGR 2026-20317.72%
Fastest Growing SegmentChronic wounds
Largest MarketNorth America

Despite this growth potential, the market faces a major hurdle regarding the substantial costs linked to these advanced therapies. Strict reimbursement policies and variable insurance coverage across different healthcare systems frequently establish financial obstacles. These economic barriers restrict patient access to essential medical interventions and potentially obstruct broader market growth.

Market Driver

The rising incidence of chronic lifestyle diseases, particularly diabetes and obesity, serves as a major driver for the adoption of wound skin substitutes. These physiological states often compromise natural healing processes, resulting in complex diabetic foot ulcers that demand cellular-based therapies for successful closure. As per the World Health Organization, over 1 billion people globally were living with obesity in 2024, a condition scientifically associated with compromised circulation and delayed wound regeneration. This vast patient population necessitates the use of bioengineered skin constructs for managing chronic defects. Furthermore, regional statistics underscore the increasing burden of metabolic disorders; according to a May 2024 report by Diabetes UK, the number of individuals living with diabetes in the UK hit a record 5.6 million, signaling a growing demographic prone to serious skin complications.

Simultaneously, the market is propelled by rapid technological progress in tissue engineering and the commercial uptake of placental and amniotic-based allografts. Manufacturers are launching versatile substitutes that modulate inflammation and minimize scarring, prompting healthcare providers to transition away from conventional dressings. This increasing approval of regenerative solutions is evident in the financial results of major industry participants. For instance, MiMedx Group Inc. reported in February 2024 that it achieved full-year net sales of USD 321.5 million for 2023, a performance largely credited to the rising adoption of its advanced wound care portfolio. Such financial figures illustrate a concrete shift toward employing bioengineered substitutes for treating hard-to-heal wounds in clinical environments.

Market Challenge

The elevated cost of advanced wound care products combined with complex reimbursement frameworks poses a significant impediment to the skin substitutes market's growth. Healthcare systems are under immense pressure to control costs, resulting in strict approval criteria for these premium biological and biosynthetic materials. Consequently, payers frequently enforce rigorous documentation standards and inconsistent payment policies, generating financial uncertainty for medical facilities. This economic climate dissuades hospitals and specialized clinics from stocking or prescribing these treatments, as the risk of claim denial or underpayment remains substantial.

This restrictive environment directly affects market accessibility and product usage rates. According to the Alliance of Wound Care Stakeholders, proposed local coverage determinations in 2023 threatened to revoke Medicare reimbursement eligibility for roughly 200 cellular and tissue-based products. Such policy changes constrain the clinical choices available to physicians and restrict patient access to therapies that could potentially save limbs. When regulatory hurdles compromise financial feasibility, the adoption of innovative skin substitutes decelerates, thereby hindering the global market's overall revenue potential and expansion.

Market Trends

The migration of wound care services toward outpatient facilities and ambulatory surgical centers is profoundly reshaping the market landscape, fueled by the demand for cost-efficient treatment delivery and enhanced patient access. Healthcare providers are increasingly decentralizing wound management, shifting away from extended hospital stays in favor of specialized clinics employing portable and automated regenerative technologies. This move facilitates the efficient treatment of defects in lower-acuity settings, alleviating the financial strain on healthcare systems while upholding clinical efficacy. According to Avita Medical's revenue update in January 2025, the company reported commercial revenue of approximately USD 18.4 million for the quarter, marking a 30% increase largely driven by the accelerated adoption of its point-of-care regenerative devices in these growing treatment settings.

Concurrently, there is a rising use of acellular dermal matrices (ADMs) and synthetic scaffolds, which present distinct benefits over conventional cellular-based therapies. Unlike cellular allografts that may pose storage difficulties and immunogenic risks, acellular xenografts and synthetic matrices offer a stable, off-the-shelf scaffold that promotes native tissue integration and neovascularization. This trend is further supported by the supply reliability and consistent structural integrity these materials offer for complex reconstruction cases. This demand is confirmed by financial figures; according to Integra LifeSciences' February 2025 financial results, the company realized an 8.2% organic growth in its Wound Reconstruction segment, bolstered by low-double-digit sales gains in its bioengineered and synthetic matrices such as DuraSorb and MicroMatrix.

Key Market Players

  • Coloplast A/S
  • Smith & Nephew plc
  • MTF Biologics
  • MIMEDX, Inc.
  • AVITA Medical, Inc.
  • MISONIX, Inc.
  • Mallinckrodt Pharmaceuticals
  • Tissue Regenix Ltd
  • Vericel Corporation
  • Integra LifeSciences Corporation

Report Scope

In this report, the Global Wound Skin Substitutes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Wound Skin Substitutes Market, By Application

  • Chronic Wounds
  • Acute Wounds
  • Others

Wound Skin Substitutes Market, By End-User

  • Hospitals
  • Ambulatory surgical Centers
  • Specialty Clinics
  • Others

Wound Skin Substitutes Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Wound Skin Substitutes Market.

Available Customizations:

Global Wound Skin Substitutes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Wound Skin Substitutes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Chronic Wounds, Acute Wounds, Others)
    • 5.2.2. By End-User (Hospitals, Ambulatory surgical Centers, Specialty Clinics, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Wound Skin Substitutes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End-User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Wound Skin Substitutes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End-User
    • 6.3.2. Canada Wound Skin Substitutes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End-User
    • 6.3.3. Mexico Wound Skin Substitutes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End-User

7. Europe Wound Skin Substitutes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End-User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Wound Skin Substitutes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End-User
    • 7.3.2. France Wound Skin Substitutes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End-User
    • 7.3.3. United Kingdom Wound Skin Substitutes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End-User
    • 7.3.4. Italy Wound Skin Substitutes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End-User
    • 7.3.5. Spain Wound Skin Substitutes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End-User

8. Asia Pacific Wound Skin Substitutes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End-User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Wound Skin Substitutes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End-User
    • 8.3.2. India Wound Skin Substitutes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End-User
    • 8.3.3. Japan Wound Skin Substitutes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End-User
    • 8.3.4. South Korea Wound Skin Substitutes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End-User
    • 8.3.5. Australia Wound Skin Substitutes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End-User

9. Middle East & Africa Wound Skin Substitutes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End-User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Wound Skin Substitutes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End-User
    • 9.3.2. UAE Wound Skin Substitutes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End-User
    • 9.3.3. South Africa Wound Skin Substitutes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End-User

10. South America Wound Skin Substitutes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End-User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Wound Skin Substitutes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End-User
    • 10.3.2. Colombia Wound Skin Substitutes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End-User
    • 10.3.3. Argentina Wound Skin Substitutes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Wound Skin Substitutes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Coloplast A/S
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Smith & Nephew plc
  • 15.3. MTF Biologics
  • 15.4. MIMEDX, Inc.
  • 15.5. AVITA Medical, Inc.
  • 15.6. MISONIX, Inc.
  • 15.7. Mallinckrodt Pharmaceuticals
  • 15.8. Tissue Regenix Ltd
  • 15.9. Vericel Corporation
  • 15.10. Integra LifeSciences Corporation

16. Strategic Recommendations

17. About Us & Disclaimer